Novartis AG ADR (NVS)vsSotera Health Co (SHC)
NVS
Novartis AG ADR
$140.98
+0.21%
HEALTHCARE · Cap: $260.70B
SHC
Sotera Health Co
$18.69
-0.05%
HEALTHCARE · Cap: $5.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4562% more annual revenue ($56.69B vs $1.22B). NVS leads profitability with a 22.5% profit margin vs 13.4%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 66/100 (B-).
NVS
Buy51
out of 100
Grade: C-
SHC
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.98
$47.58 premium
Intrinsic value data unavailable for SHC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Strong operational efficiency at 38.0%
Earnings expanding 570.0% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 8.0x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 3.41 is elevated, increasing financial risk.
Key Dynamics to Monitor
SHC carries more volatility with a beta of 1.78 — expect wider price swings.
SHC is growing revenue faster at 9.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SHC scores higher overall (66/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?